IP Library › Granted Patent US 10,816,544
Granted Patent B2
US 10,816,544 · App. 15/887,941 · Granted Oct 27, 2020

Methods for measuring small molecule affinity to cereblon

Inventors: Philip Paul Chamberlain (San Diego, CA); Mary Matyskiela (San Diego, CA); Godrej Khambatta (San Diego, CA)
Assignee: CELGENE CORPORATION
G01N33/542C07K14/47G01N2333/4703G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,816,544
App. No.
15/887,941
Granted
Oct 27, 2020
Kind
B2
Abstract

A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.

Claims (14)

1. A method of measuring the affinity of a compound to cereblon (CRBN) or determining if a compound binds to cereblon (CRBN), the method comprising:

contacting the compound with a complex, wherein the complex comprises

(i) a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and

(ii) a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN;

measuring fluorescence resonance energy transfer (FRET) after contacting the compound with the complex; and

determining the binding and/or affinity of the compound to CRBN based on the measured FRET; and

wherein the Cy5-conjugated small molecule has a structure of Formula (I)

wherein the Cy5-conjugated small molecule binds in a hydrophobic tri-tryptophan pocket formed by Trp380, Trp386, and Trp400 on the CRBN.

2. The method of claim 1 , wherein the complex further comprises a DNA damage-binding protein 1 (DDB1).

3. The method of claim 1 , wherein the method further comprises measuring FRET prior to contacting the compound with the complex.

4. The method of claim 3 , further comprises determining that the compound binds to the CRBN if FRET is reduced after contacting the compound with the complex.

5. The method of claim 1 , wherein FRET is observed by exciting at 340 nm and monitoring emission at 615 nm (non-FRET emission) and 665 nm (FRET emission).

6. The method of claim 5 , wherein a first FRET efficiency is determined prior to contacting the compound with the complex, and a second FRET efficiency is determined after contacting the compound with the complex, and wherein FRET efficiency is the ratio of FRET emission at 665 nm to non-FRET emission at 615 nm.

7. The method of claim 6 , further comprises determining that the compound binds to the CRBN if the second FRET efficiency is less than the first FRET efficiency.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2018
From: CHAMBERLAIN, PHILIP PAUL; MATYSKIELA, MARY; KHAMBATTA, GODREJ
To: CELGENE CORPORATION
Reel/Frame 046203/0575 →
Continuity (2)
Provisional Application 62454654 · Feb 3, 2017
Related Publication 20180224435A1 · Aug 9, 2018